

# Respiratory Syncytial Virus Vaccine, Adjuvanted



AHFS Class: 80:12 – Vaccines (tofc-80)

## Respiratory Syncytial Virus Vaccine, Adjuvanted (AHFS DI)

**Respiratory Syncytial Virus Vaccine, Adjuvanted**

### Introduction

Respiratory syncytial virus (RSV) vaccine, adjuvanted is a protein subunit vaccine that stimulates active immunity to RSV infection; the vaccine is a recombinant stabilized pre-fusion F protein (RSVpreF3) antigen with an ASO1<sub>E</sub> adjuvant.<sup>1,2,8.</sup>

### Uses

#### ■ Prevention of Lower Respiratory Tract Disease Caused by RSV in Older Adults

RSV vaccine, adjuvanted is used for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals ≥60 years of age and in individuals 50–59 years of age who are at increased risk for LRTD caused by RSV.<sup>1.</sup>

#### *Clinical Experience*

Efficacy of RSV vaccine, adjuvanted in adults ≥60 years of age is based principally on an ongoing randomized, placebo-controlled, observer-blinded, clinical study (NCT04886596).<sup>1,2.</sup> Patients with medically stable chronic medical conditions (e.g., diabetes, hypertension, or cardiac disease) were allowed to participate; however, the study excluded patients who were immunocompromised due to disease or immunosuppressive treatments.<sup>1,2.</sup> The primary vaccine efficacy endpoint was prevention of a first episode of confirmed RSV A- and/or B-associated LRTD during the first season.<sup>1,2.</sup> Lower respiratory symptoms were defined as new or increased sputum, new or increased cough, new or increased dyspnea; lower respiratory signs were defined as new or increased wheezing, crackles/rhonchi, respiratory rate ≥20 respirations/minute, low or decreased oxygen saturation (O<sub>2</sub> saturation <95% or ≤90% if baseline is <95%), or need for oxygen supplementation.<sup>1,2.</sup> LRTD was defined as at least 2 lower respiratory symptoms/signs, including at least 1 lower respiratory sign for at least 24 hours, or at least 3 lower respiratory symptoms for at least 24 hours.<sup>1,2.</sup> A severe RSV-associated LRTD was defined as a PCR-confirmed RSV-associated LRTD with at least 2 lower respiratory signs, or preventing normal, everyday activities or requiring supportive therapy.<sup>1.</sup>

Participants included in the study were randomized to receive either a single dose of RSV vaccine, adjuvanted or placebo.<sup>1,2.</sup> The median age of participants in the population evaluated for efficacy over the first RSV season was 69 years; 51.7% were female, 79.4% were white, 8.7% were Black, and 7.6% were Asian.<sup>1.</sup> At baseline, 39.3% of participants had at least 1 comorbidity of interest; 19.7% of participants had an underlying cardiorespiratory condition (chronic obstructive pulmonary disease, asthma, any chronic respiratory/pulmonary disease, or chronic heart failure) and 25.8% of participants had endocrine and metabolic conditions (diabetes, advanced liver or renal disease).<sup>1.</sup> The median duration of efficacy follow-up was 6.7 months for the primary efficacy analysis over the first RSV season.<sup>1,2.</sup>

Compared to placebo, RSV vaccine, adjuvanted significantly reduced the risk of developing RSV-associated LRTD by 82.6% during the first RSV season in participants 60 years of age or older, which met the success criterion for the primary study objective; the vaccine also significantly reduced the risk of developing severe RSV-associated LRTD by 94.1% compared with placebo.<sup>1,2.</sup> Vaccine efficacy against RSV A- and RSV B-associated LRTD cases was 84.6 and 80.9%, respectively.<sup>1.</sup> Efficacy against RSV-related LRTD was 81% among participants 60 to 69 years of age and 93.8% among those 70 to 79 years of age; insufficient cases were available to reliably determine efficacy for patients ≥80 years of age.<sup>2.</sup> In participants with at least 1 comorbidity of interest, vaccine efficacy over the first RSV season was 94.6%.<sup>1.</sup> The study was not powered to estimate efficacy against hospitalization, severe RSV illness requiring respiratory support, or death.<sup>2.</sup> The efficacy analysis for RSV vaccine, adjuvanted also included data up to the end of the second and third seasons in the Northern Hemisphere; participants 60 years of age or older who received a single dose of the RSV vaccine or placebo prior to season 1 were included in the cumulative analysis.<sup>1.</sup> At a median follow-up of 17.8 months over 2 RSV seasons, vaccine efficacy of 1 dose was 67.2%; at a median follow-up of 30.6 months over 3 RSV seasons, vaccine efficacy was 62.9%.<sup>1,6.</sup> Vaccine efficacy over 2 RSV seasons was 65.4% among participants 60 to 69 years of age and 74.9% among those 70 to 79 years of age.<sup>1.</sup> Vaccine efficacy over 3 RSV seasons was 60.3% among participants 60 to 69 years of age and 70.6% among those 70 to 79 years of age.<sup>1.</sup> Insufficient cases were available to reliably determine efficacy for patients ≥80 years of age.<sup>1.</sup> In participants with at least 1 comorbidity of interest, vaccine efficacy over 2 RSV seasons was 66.7% and vaccine efficacy over 3 RSV seasons was 64.7%.<sup>1.</sup>

The effectiveness of RSV vaccine, adjuvanted in individuals 50 through 59 years of age with chronic medical conditions was assessed by a comparison of RSV neutralizing antibody responses induced by the vaccine in this age group with the antibody responses induced by the vaccine in individuals 60 years of age and older.<sup>1.</sup> The neutralizing antibody responses to RSV-A and RSV-B subtypes in individuals 50 through 59 years of age met the criteria for immunobridging; the difference in seroresponse rate was ≤10%, which demonstrated noninferiority.<sup>1.</sup>

#### *Clinical Perspective*

RSV causes respiratory tract infections in individuals of all age groups.<sup>3,4.</sup> In older adults, RSV is a common cause of LRTD that can lead to severe disease requiring hospitalization for respiratory support, including supplemental oxygen and/or mechanical ventilation.<sup>4.</sup> Infection rates, intensive care unit (ICU) stays, and mortality are similar among older adults hospitalized with respiratory viral infections caused by RSV and influenza.<sup>3.</sup> Severity of RSV disease increases with age and comorbidities (e.g.,

chronic obstructive pulmonary disease, congestive heart failure, asthma).<sup>3</sup>

The US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends that all adults ≥75 years of age receive a single dose of RSV vaccine.<sup>8</sup> ACIP also recommends that adults 50–74 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.<sup>15,16</sup> Clinical considerations that place these adults at increased risk of severe RSV include chronic lung or respiratory disease, chronic cardiovascular disease, moderate or severe immune compromise, diabetes mellitus with end-organ damage, severe obesity (BMI ≥40 kg/m<sup>2</sup>), neurologic or neuromuscular conditions causing impaired airway clearance or respiratory muscle weakness, advanced chronic kidney disease, chronic liver disease, chronic hematologic disorders, residence in a nursing home, and other chronic medical conditions that a healthcare provider determines increases risk of severe disease due to respiratory infection.<sup>8</sup> Additional clinical considerations may be published by the CDC as they become available.<sup>15</sup> At this time, RSV vaccination is recommended as a single dose only; individuals who have already received RSV vaccination are not recommended to receive another dose.<sup>15</sup>

The Center for Infectious Disease Research and Policy (CIDRAP) has established the Vaccine Integrity Project to provide evidence-based guidance on key immunizations for the upcoming respiratory season focusing on influenza, RSV, and COVID.<sup>77</sup> The Vaccine Integrity Project is an initiative to safeguard vaccine use in the US and disseminate evidence-based information for informed decision-making.<sup>77</sup> A multi-disciplinary group of experts has been convened to prepare recommendations for the upcoming 2025-2026 fall-winter respiratory season.<sup>77</sup> CIDRAP will provide updates on the initiative's progress as they become available.<sup>77</sup> For additional information see, <https://www.cidrap.umn.edu/vaccine-integrity-project> (<https://www.cidrap.umn.edu/vaccine-integrity-project>).

---

## Dosage and Administration

### ■ General

#### *Dispensing and Administration Precautions*

Appropriate medications and supplies for managing allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following vaccine administration.<sup>1,5</sup>

Syncope may occur following administration of injectable vaccines.<sup>1,5</sup> Procedures should be in place to avoid injury from fainting; if syncope develops, patients should be observed until the symptoms resolve.<sup>1,5</sup>

### ■ Administration

#### *IM Administration*

Respiratory syncytial virus (RSV) vaccine, adjuvanted suspension for injection is administered only by IM injection.<sup>1</sup> IM injections should preferably be made into the deltoid muscle.<sup>2,5</sup>

The vaccine preparation is supplied as a single-dose vial of lyophilized antigen component to be reconstituted with a vial of adjuvant suspension component.<sup>1</sup> Prepare the vaccine by reconstituting the lyophilized antigen component (sterile white powder) with the accompanying adjuvant suspension component (opalescent, colorless to pale brownish sterile liquid).<sup>1</sup> Use only the supplied adjuvant suspension component for reconstitution.<sup>1</sup> Using aseptic technique, withdraw the entire contents of the vial containing the adjuvant suspension component (liquid) with a sterile needle and syringe.<sup>1</sup> Slowly transfer entire contents of the syringe into the lyophilized antigen component vial.<sup>1</sup> Gently swirl the vial until the powder is completely dissolved; do *not* shake vigorously.<sup>1</sup> The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid and should not be used if it is discolored or contains particulates.<sup>1</sup> After reconstitution, administer the vaccine immediately or store under refrigeration (2–8°C) or at room temperature (up to 25°C); protect from light and use within 4 hours.<sup>1</sup> Discard the reconstituted vaccine if not used within 4 hours.<sup>1</sup>

To administer a dose of the vaccine, withdraw 0.5 mL of reconstituted vaccine for IM injection.<sup>1</sup>

RSV vaccine, adjuvanted lyophilized antigen and adjuvant suspension component vials should be stored at 2–8°C in the original carton, protected from light, prior to use.<sup>1</sup> Do not freeze.<sup>1</sup>

### ■ Dosage

#### *Adult Dosage*

#### Prevention of Lower Respiratory Tract Disease Caused by RSV in Older Adults.

For the prevention of lower respiratory tract disease caused by RSV in adults ≥60 years of age and adults 50 through 59 years of age at increased risk, a single 0.5 mL dose of RSV vaccine, adjuvanted should be administered by IM injection.<sup>1</sup>

---

## Cautions

### ■ Contraindications

History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.<sup>1</sup>

### ■ Warnings/Precautions

#### *Guillain-Barré Syndrome*

Results of a postmarketing observational study suggest that the risk of Guillain-Barré syndrome (GBS) may be increased during the 42 days following vaccination with RSV vaccine, adjuvanted.<sup>1,10</sup> The observational study used Medicare claims data to assess the risk of GBS following vaccination with the RSV vaccine in a self-controlled case series analysis using a risk window of 1 to 42 days post vaccination and control window of 43 to 90 days post vaccination.<sup>1</sup> An increased risk of GBS was observed during the 42 days following vaccination, with an incidence rate ratio of 2.46 and an estimated 7 excess cases of GBS per million doses administered to individuals 65 years of age and older.<sup>1</sup> Based on the totality of evidence including data from clinical trials, reports to the Vaccine Adverse Event Reporting System (VAERS), and the postmarketing study, FDA has determined that the current evidence suggests an increased risk of GBS with RSV vaccine, adjuvanted, but the available evidence is insufficient to establish a causal relationship.<sup>10</sup>

### ***Preventing and Managing Allergic Vaccine Reactions***

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of RSV vaccine, adjuvanted.<sup>1</sup>

#### ***Syncope***

Syncope (fainting) may occur in association with administration of injectable vaccines, including RSV vaccine, adjuvanted.<sup>1</sup> Procedures should be in place to avoid injury from fainting.<sup>1</sup>

#### ***Altered Immunocompetence***

Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to RSV vaccine, adjuvanted.<sup>1</sup>

#### ***Specific Populations***

##### **Pregnancy.**

RSV vaccine, adjuvanted is not approved for use in persons <50 years of age.<sup>1</sup>

In a randomized, controlled trial that enrolled pregnant individuals, preterm births were higher in those who received an investigational *unadjuvanted* RSV vaccine that contained the same RSVPreF3 antigen as RSV, adjuvanted.<sup>1</sup>

##### **Lactation.**

RSV vaccine, adjuvanted is not approved for use in persons <50 years of age.<sup>1</sup> It is not known whether the vaccine is distributed into human milk; no human or animal data are available to assess vaccine effects on the breastfed infant or on milk production.<sup>1</sup> The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for vaccination and any potential adverse effects on the breastfed child from the vaccine or from the underlying maternal condition (the susceptibility to disease prevented by the vaccine).<sup>1</sup>

##### **Pediatric Use.**

RSV vaccine, adjuvanted is not approved for use in persons <50 years of age.<sup>1</sup> Evidence from animal models strongly suggests that RSV vaccine, adjuvanted is unsafe in children <2 years of age because of an increased risk of enhanced respiratory disease.<sup>1</sup> Safety and effectiveness of the vaccine in individuals 2 to 17 years of age have not been established.<sup>1</sup>

##### **Geriatric Use.**

In the principal efficacy study, 55.8% of patients were 60-69 years of age, 36% were 70-79 years of age, and 8.2% were ≥80 years of age.<sup>1,2</sup> Efficacy against RSV-related lower respiratory tract disease was 81% among participants 60 to 69 years of age and 93.8% among participants 70 to 79 years of age; insufficient cases were available to determine efficacy in patients ≥80 years of age.<sup>1</sup>

## **■ Common Adverse Effects**

The most common adverse reactions occurring in ≥10% of patients 60 years of age and older receiving RSV vaccine, adjuvanted were injection site pain, fatigue, myalgia, headache, and arthralgia.<sup>1</sup>

The most common adverse reactions occurring in ≥10% of patients 50 through 59 years of age receiving RSV vaccine, adjuvanted were injection site pain, fatigue, myalgia, headache, arthralgia, erythema, and swelling.<sup>1</sup>

## **Drug Interactions**

### **■ Influenza Vaccine**

In open-label studies, participants received a single dose of RSV vaccine, adjuvanted (Arexvy<sup>®</sup>) and quadrivalent influenza virus vaccine inactivated (Fluarix<sup>®</sup>) simultaneously or separated by 1 month.<sup>1</sup> There was no evidence of interference in the immune response to any of the antigens contained in both concomitantly administered vaccines.<sup>1</sup>

## **Description**

Respiratory syncytial virus vaccine, adjuvanted is a recombinant RSV glycoprotein F stabilized in pre-fusion conformation (RSVPreF3) with AS01<sub>E</sub> adjuvant.<sup>1</sup> The AS01<sub>E</sub>-based adjuvant is composed of 3-*O*-desacyl-4'-monophosphoryl lipid A (MPL) from *Salmonella minnesota* and QS-21, a saponin purified from plant extract *Quillaja saponaria* Molina, combined in a liposomal formulation.<sup>1</sup>

Respiratory syncytial virus vaccine, adjuvanted stimulates an immune response against RSVPreF3 to protect against lower respiratory tract disease (LRTD) caused by RSV.<sup>1</sup> RSV F glycoprotein (pre-fusion and post-fusion) mediates viral fusion and host-cell entry, elicits neutralizing antibodies, and is highly conserved across the 2 RSV subtypes (A and B).<sup>2</sup> In animal studies, significantly higher neutralizing activity occurred following immunization with pre-fusion forms of the F protein antigen compared to post-fusion forms.<sup>2</sup> Following vaccination with AS01E-adjuvanted formulations, RSV-specific CD4+ T-cell frequencies increased in older adults to similar levels to those observed in young adults.<sup>2</sup>

---

## Advice to Patients

The following information contains important points for the clinician to discuss with patients during counseling. For more comprehensive monographs suitable for distribution to the patient, please refer to the *AHFS Patient Medication Information* monographs available from MedlinePlus (<https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v;project=medlineplus>) (in English and Spanish; written at a 6th- to 8th-grade reading level).

Advise patients of the potential benefits and risks of respiratory syncytial virus (RSV) vaccine, adjuvanted vaccination.<sup>1</sup>

Advise patients about the potential for adverse reactions that have been observed following vaccine administration.<sup>1</sup>

Provide the Vaccine Information Statements, which are available free of charge at the Centers for Disease Control and Prevention (CDC) website (<https://www.cdc.gov/vaccines/hcp/vis/> (<https://www.cdc.gov/vaccines/hcp/vis/>)).<sup>1</sup>

Clinicians or individuals can report any adverse reactions that occur following vaccination to the Vaccine Adverse Event Reporting System (VAERS) at 800-822-7967 or <https://vaers.hhs.gov/> (<https://vaers.hhs.gov/>).<sup>1</sup>

Advise patients to inform their clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.<sup>1</sup>

Advise patients to inform their clinician if they are or plan to become pregnant or plan to breast-feed.<sup>1</sup>

Inform patients of other important precautionary information.<sup>1</sup>

---

## Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer's labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

---

## Preparations

*Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.*

**[Respiratory Syncytial Virus Vaccine, Adjuvanted](https://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm?sugg=NonProprietaryName&ApptName=Respiratory+Syncytial+Virus+Vaccine%2C+Adjuvanted&collapse=1) (<https://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm?sugg=NonProprietaryName&ApptName=Respiratory+Syncytial+Virus+Vaccine%2C+Adjuvanted&collapse=1>)**

### Parenteral

*Injectable suspension, for IM use only*

Each 0.5 mL contains 120 mcg of recombinant respiratory syncytial virus glycoprotein F stabilized in pre-fusion conformation (RSVPreF3) antigen **Arexvy**<sup>®</sup> (*Supplied as a single-dose vial of lyophilized antigen component to be reconstituted with accompanying vial of adjuvant suspension component*), GlaxoSmithKline (<https://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm?sugg=LabelerName&ApptName=GlaxoSmithKline&collapse=1>)

---

## Related Resources

AHFS Patient Medication Information (<https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v;project=medlineplus&query=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted>) and other related patient health topics (MedlinePlus)

ASHP Drug Shortages Resource Center (<https://www.ashp.org/Drug-Shortages>)

CCRIS (<https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?db+ccris:%22Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted%22>) (Chemical Carcinogenesis Research Information System)

ChemIDplus (<https://chem.nlm.nih.gov/chemidplus/name/Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted>)

Biochemical Data Summary ([http://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted&searcher=drugs&approved=1&vet\\_approved=1&nutraceutical](http://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted&searcher=drugs&approved=1&vet_approved=1&nutraceutical))

(US and Canada)

Clinical Trials (<https://www.clinicaltrials.gov/ct/search?submit=Search&term=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted>)

DailyMed (<https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted>) (drug labels)

DART (<https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?db+dart:%22Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted%22>) (Developmental

and Reproductive Toxicology Database)

Drugs@FDA (<https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&SearchTerm=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted>) (approval information)

European Medicines Agency ([https://www.ema.europa.eu/en/search/search?search\\_api\\_views\\_fulltext=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted](https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted))

FDA National Drug Code Directory (<https://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm?sugg=NonProprietaryName&ApptName=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted&collapse=1>)

FDA Recalls, Market Withdrawals, and Safety Alerts (<https://www.fda.gov/Safety/Recalls/default.htm>)

HSDb (<https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:%22Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted%22>) (Hazardous Substances Data Bank)

Inxight Drugs (<https://drugs.ncats.io/substances?q=%22Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted%22>) (National Center for Advancing Translational Sciences)

LactMed (drug effects on breastfeeding) (<https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted%22+%29>)

New Drug Approvals (<https://ahfs.ashp.org/drug-assignments.aspx>)

Orange Book (<https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm?panel=0&drugname=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted>) (therapeutic equivalence)

PharmGKB (<https://www.pharmgkb.org/search?connections&gaSearch=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted&query=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted>) (Pharmacogenomic data from PharmGKB)

Pillbox (*beta*) ([https://pillbox.nlm.nih.gov/pillimage/search\\_results.php?submit=Search&spid=&gettingredient=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted](https://pillbox.nlm.nih.gov/pillimage/search_results.php?submit=Search&spid=&gettingredient=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted)) (drug identification and images)

PubMed (<https://www.ncbi.nlm.nih.gov/pubmed?DB=pubmed&term=Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted%5BAll+Fields%5D>) (scientific journals)

Safety-related Labeling Changes (<https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges>) (FDA/CDER)

ToxLine (<https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+toxline:%22Respiratory%20Syncytial%20Virus%20Vaccine,%20Adjuvanted%22>) (Toxicology Literature Online)

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

AHFS Drug Information®. © Copyright, 1959-2026, American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, MD 20814.

Original Publication Date: May 25, 2023.

Selected Revisions: October 10, 2025.

Database Extraction: 02/06/2026 17:49:19 +0000+

## References

1. GlaxoSmithKline Biologicals SA. Arexvy® (Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted) prescribing information. Durham, NC; 2025 Aug.
2. Papi A, Ison MG, Langley JM, et al.; AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. *N Engl J Med*. 2023 Feb 16;388(7):595-608.
3. Kodama F, Nace DA, Jump RLP. Respiratory Syncytial Virus and Other Noninfluenza Respiratory Viruses in Older Adults. *Infect Dis Clin North Am*. 2017 Dec;31(4):767-790.
4. US Food and Drug Administration. Center for Biologics Evaluation and Research. Submission tracking number (STN): 125775: BLA Clinical review memorandum. From FDA website. Accessed 2023 Jun 13. [Web] (<https://cacmap.fda.gov/vaccines-blood-biologics/arexvy>)
5. Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Accessed on 2023 Jun 26. [Web] (<https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf>)
6. Ison MG, Papi A, Athan E et al. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. *Clin Infect Dis*. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC11175669
8. Britton A, Roper LE, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices – United States, 2024. *MMWR Morb Mortal Wkly Rep* 2024;73:696-702. [Web] ([https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm?s\\_cid=mm7332e1\\_w](https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm?s_cid=mm7332e1_w))
9. Melgar M, Britton A. Center for Disease Control and Prevention. RSV vaccination in adults: ACIP work group interpretations. October 24, 2024. [Web] (<https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/06-RSV-Adult-Melgar-508.pdf>)
10. Food and Drug Administration. FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy. From FDA website. [Web] ([https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and?utm\\_medium=email&utm\\_source=govdelivery](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and?utm_medium=email&utm_source=govdelivery))
15. Centers for Disease Control and Prevention (CDC), ACIP Recommendations updated Aug 8, 2025. From CDC website. [Web] (<https://www.cdc.gov/acip/vaccine-recommendations/index.html>)

16. Centers for Disease Control and Prevention (CDC), RSV vaccines updated Aug 18, 2025. From CDC website.[Web] (<https://www.cdc.gov/rsv/vaccines/index.html>)
77. Center for Infectious Disease Research and Policy (CIDRAP). Vaccine Integrity Project. From the CIDRAP website.[Web] (<https://www.cidrap.umn.edu/vaccine-integrity-project>)

---

**About ASHP**

ASHP represents pharmacists who serve as patient care providers in acute and ambulatory settings. The organization's nearly 55,000 members include pharmacists, student pharmacists, and pharmacy technicians. For more than 75 years, ASHP has been at the forefront of efforts to improve medication use and enhance patient safety. For more information about the wide array of ASHP activities and the many ways in which pharmacists advance healthcare, visit ASHP's website (<https://www.ashp.org>), or its consumer website (<https://www.safemedication.com>).

**Contact Us**

ASHP  
4500 East-West Highway, Suite 900  
Bethesda, Maryland 20814

Customer Service  
1-866-279-0681  
[custserv@ashp.org](mailto:custserv@ashp.org) (<mailto:custserv@ashp.org>)  
[softwaresupport@ashp.org](mailto:softwaresupport@ashp.org)  
(<mailto:softwaresupport@ashp.org>)

© 2026. American Society of Health-System Pharmacists. All Rights Reserved. | Copyright (<http://www.ashp.org/copyright>) | Trademark (<http://www.ashp.org/trademark>) | Privacy Policy (<http://www.ashp.org/privacy>) |



(<https://itunes.apple.com/us/app/ahfs-clinical-drug-information/id1068281731>)